Novel technology platform could be used across a wide range of rare diseases, so executive team and board want an independent, evidence-based view of commercial opportunity to complement the scientific analysis.


Interviews with KOL physician-scientists to understand unmet need and applicability of technology to targets, detailed pipeline analysis, market modeling and epidemiology research.

“This is perfect.  This is exactly what the board needed to see so we can move ahead aggressively on the best genes.  We will be back in three months to work on the next batch of targets.” – VP Business Development